logo
Plus   Neg
Share
Email

Babcock Sells Context Information Security To Accenture For £107 Mln; Stock Dips

Shares of Babcock International Group plc (BAB.L) were losing around 3 percent after the aerospace and defence company said Friday that it has sold Context Information Security, a cyber defence consultancy, to Professional services company Accenture Plc (ACN) for a cash consideration of 107 million pounds.

London-based Context provides high-end cyber defense across a range of industries including financial services, government, aerospace and defence and critical infrastructure. It employs over 250 people across the UK, Germany, USA and Australia.

Babcock said the deal continues its strategy of streamlining portfolio by realising value from businesses outside its core strategy.

In a statement, Accenture said the acquisition strengthens Accenture Security's existing portfolio and becomes part of Accenture's cyber defense offerings. The addition of Context's more than 250 employees will further deepen Accenture Security's services to clients.

Kelly Bissell, a senior managing director at Accenture, who leads Accenture Security, said, "The deal signals continued aggressive growth for Accenture Security and gives us a new branch of talented family members to help clients grow their business with confidence and resilience."

Earlier in January, Accenture agreed to acquire Symantec's Cyber Security Services business.

In London, Babcock shares were trading at 415 pence, down 2.95 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Avalon Furniture is recalling about 9,500 units of Cottage Town Bedroom Furniture collection sold through Rooms To Go due to violation of federal lead paint ban, the U.S. Consumer Product Safety Commission said in a statement. According to the agency, the base coat paint used on pieces within the furniture collection contains levels of lead that exceed the federal lead paint standard. Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial. Shares of Moderna Inc. (MRNA) slipped over 5% on Thursday after a report claimed that the biotechnology company's late-stage trial for a coronavirus vaccine will be delayed. Moderna is developing mRNA-1273 in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). The...
Follow RTT